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We recently reported that epicardial fat thickness is signiﬁcantly
associated with the severity of liver ﬁbrosis in patients with non-
alcoholic fatty liver disease (NAFLD), and that in this clinical set-
ting, morphological and functional cardiac alterations by echocar-
diography are inversely related with the severity of liver damage
[1]. Of note, these associations were maintained after correction
for both cardiometabolic and hepatic confounders including vis-
ceral adiposity.
In their letter [10], Corrao and colleagues suggest that some
cytokines/adipocytokines as well as adiponectin, transforming
growth factor b1, e-selectin, endothelin, and ﬁbroblast growth
factor 21 could explain the link we observed between the severity
of liver disease and the presence of cardiac alterations. In this line
in our paper we already suggested that ‘‘the inﬂammatory state
that characterize NAFLD/NASH might be able to act systemically,
affecting the homeostasis of different organs, including the heart,
as already demonstrated for systemic atherosclerosis [2] and kid-
ney damage [3]’’. Therefore we are planning to study the relation-
ship between cytokines/adipocytokines levels, liver damage and
cardiac alterations in NAFLD, as well as the role of genetic vari-
ants associated with NAFLD and its severity on the presence of
cardiac alterations. We recently reported that gene variants in
the PNPLA3 and TMS6F2 genes, can modulate the risk of
atherosclerosis as well as the occurrence of cardiovascular events
in patients with NAFLD or at high NAFLD risk [4,5].
Corrao and colleagues also question the approach we used for
the multivariate model, assessing variables independently associ-
ated with severe liver ﬁbrosis. Speciﬁcally, they raised concerns
about the inclusion in the model of both visceral obesity and epi-
cardial fat, because considered as a phenomenon of collinearity.
We thank the authors to correctly explain this phenomenon
and the implication that it can produce on data interpretation.
However, we respectfully think that our analysis is not biased
by collinearity. Epicardial fat [6], as well as other ectopic fat
depots like liver or dorsocervical fat [7], are obviously strongly
related to visceral obesity. However, they do not depend on vis-
ceral obesity only, because they can have an independent role
in affecting liver and systemic damage. In this line, cross-section-
al and prospective studies showed that both liver and visceral fat
are independent risk factors for presence and occurrence of car-
diovascular events [8,9]. So, we included both visceral and epicar-
dial fat in the model for ﬁbrosis to demonstrate that the effect of
epicardial fat is independent of that of visceral fat.
Finally, in response to Ulucan and colleagues [11] we agree
with the authors that the interference of epicardial fat with the
autonomic nervous system could be one of the mechanisms link-
ing this ectopic fat to liver damage. Accordingly, further clinical
and experimental studies are needed in this topic.Journal of Hepatology 2015 vol. 62 j 1204–1218 1215
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